Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Biofrontera AG BFRA
$2.67
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
7.54
-
week52low
1.50
-
Revenue
30346000
-
P/E TTM
-5
-
Beta
1.54797400
-
EPS
-0.61400000
-
Last Dividend
0.12600000
-
Next Earnings Date
11 апр 2022 г. в 04:00
Описание компании
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Benchmark | Buy | Buy | 20 апр 2020 г. |
| Benchmark | Buy | Buy | 20 ноя 2019 г. |
| Benchmark | Speculative Buy | 09 мар 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
BFRI Stock Earnings: Biofrontera Misses EPS, Revenue Estimates
InvestorPlace
12 мая 2023 г. в 08:12
Biofrontera (NASDAQ: BFRI ) reported results for the first quarter of 2023. Biofrontera posted a loss per share of 28 cents.